SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. , today announced it plans to issue earnings results for the third quarter and nine months of 2007 ended Sept. 30, 2007, after the close of market on Nov. 12, 2007. The company's earnings conference call will take place Nov. 12, 2007, at 2 p.m. PST (5 p.m. EST).
Trubion also announced that it will provide a summary of data presented at the American College of Rheumatology (ACR) Annual Scientific Meeting after the close of market on Nov. 8, 2007. The company will conduct a conference call to discuss these results on Nov. 8, 2007, at 2 p.m. PST (5 p.m. EST).
Both live events will be available for viewing on Trubion's Web site at http://investors.trubion.com/events.cfm.
ACR Conference Call: 2 p.m. PST / 5 p.m. EST, Nov. 8, 2007
Participants are invited to call (888) 204-4368 or (913) 312-1303. A replay of the discussion will be available after the call by visiting Trubion's Web site or calling (888) 203-1112 or (719) 457-0820, and entering 4403352.
Third-Quarter Earnings Conference Call: 2 p.m. PST / 5 p.m. EST, Nov. 12, 2007
Participants are invited to call (888) 208-1386 or (913) 981-5593. A replay of the discussion will be available after the call by visiting Trubion's Web site or calling (888) 203-1112 or (719) 457-0820, and entering 4262106.
About Trubion
Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP(TM) custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug application for its lead product candidate, TRU-015, which is currently being tested in a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Subject to satisfactory completion of preclinical testing of TRU-016, the company expects to file an IND for TRU-016 in the fourth quarter of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit http://www.trubion.com.
jdenike@trubion.comhttp://www.trubion.com
CONTACT: Jim DeNike, Senior Director, Corporate Communications of Trubion
Pharmaceuticals, Inc., +1-206-838-0500, jdenike@trubion.com
Web site: http://www.trubion.com/
